Novel nanomolar inhibitors of the gram negative bacterial heptose pathway

<none>

Programme Social programme Plenary speakers Keynote speakers 1st EuroCarb Young Researcher (ECYR) Workshop CarboMet Workshop Mini symposium: Glycobiology at the LUMC and beyond Favourites/Agenda

Social programme

Plenary speakers

Keynote speakers

1st EuroCarb Young Researcher (ECYR) Workshop

CarboMet Workshop

Mini symposium: Glycobiology at the LUMC and beyond

Favourites/Agenda

Photos

Venue & Travel Venue Accommodation City of Leiden Travel directions

Venue

Accommodation

City of Leiden

Travel directions

Committees

Home

Novel nanomolar inhibitors of the gram negative bacterial heptose pathway

Markus Blaukopf 1 , Marek Barath 1 , Dmytro Atamanyuk 2 , Vincent Gerusz 2 , Stéphanie Floquet 2 , Damien Bonnard 2 , Francois Moreau 2 , Paul Kosma 1

1 University Of Natural Resources And Life Sciences, Vienna, Vienna, Austria, 2 Mutabilis, Romainville, France

A threat to global health is presently associated with the increase of multidrug-resistant bacteria, for several of which common antibiotics are not effective anymore.[1] Novel approaches, such as the antivirulence concept, are therefore urgently needed to identify bacterial targets and develop appropriate compounds with new modes of action. Various isomers of heptoses play crucial roles in bacteria. Glycero-D-manno-heptoses have been found in capsular polysaccharides, O-antigens and the core region of lipopolysaccharide (LPS).[2] The biosynthesis of heptoses and the nucleotide-activated ADP- and GDP-heptoses has been elucidated in great detail lead.[3] The first enzymatic step common to all pathways is catalyzed by the sedoheptulose-7-phosphate isomerase GmhA, which notably requires a zinc atom for activity.[4]

Starting from suitable ribose and hexose precursors, a series of derivatives, based on GmhA’s open chain substrate sedoheptulose-7-phosphate and a zinc chelating formylhydroxamate scaffold have been prepared as terminal phosphate and phosphonate analogues, some of which were able to interfere with the heptose biosynthesis in a nanomolar concentration range. Bacteria grown in the presence of one of these inhibitors and glucose-6-phosphate to activate the UhpT transport system expressed a deep rough phenotype and were effectively sensitized to erythromycin.[5] These findings further support the search for innovative ways to fight bacterial infections.[6]

Antivirulence approach aided by new potential antimicrobial substances

Brown, E. D.; Wright, G. D. Nature 2016, 529, 336.

Kosma, P. Curr. Org. Chem. 2008, 12, 1021.

Valvano M. A.; Messner P.; Kosma P. Microbiol. 2002, 148, 1979.

Harmer, N. J. Mol. Biol. 2010, 400, 379.

Gerusz, V.; Vincent, S. P.; Oxoby, M.; Atamanyuk, D.; Moreau, F.; Tikad, A.; Andaloussi, M. WO2012073214 (2010); Atamanyuk, D.; Gerusz, V. WO2013178622 (2013); Atamanyuk, D.; Gerusz, V.; Moreau, F.; Henryon, V.; Monbrun, J.; Airiau, E. WO2014067904A1 (2014).

Durka, M.; Tikad, A.; Périon, R.; Bosco, M.; Andaloussi, M.; Floquet, S.; Malacain, E.; Moreau, F.; Oxoby, M.; Gerusz, V.; Vincent, S. P. Chem. Eur. J. 2011, 17, 11305

Contact eurocarb@eurocarb2019.com for general questions about EUROCARB2019, or codee@eurocarb2019.com for scientific questions.

Leiden University / Leiden Institute of Chemistry lic.leidenuniv.nl

European Carbohydrate Organisation

Congress by Design www.congressbydesign.com